This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Becomes the first rehab & recovery center in east India to earn NABH accreditation
India Business grew by 11.9% YoY to Rs. 1196.2 crore
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The inspection was concluded with zero observations
Subscribe To Our Newsletter & Stay Updated
